



HAL
open science

Subcutaneous vaccination with a live attenuated *Yersinia pseudotuberculosis* plague vaccine

Anne Derbise, Chloé Guillas, Christiane Gerke, Elisabeth Carniel, Javier Pizarro-Cerdá, Christian E. Demeure

► To cite this version:

Anne Derbise, Chloé Guillas, Christiane Gerke, Elisabeth Carniel, Javier Pizarro-Cerdá, et al.. Subcutaneous vaccination with a live attenuated *Yersinia pseudotuberculosis* plague vaccine. *Vaccine*, 2020, 38 (8), pp.1888-1892. 10.1016/j.vaccine.2020.01.014 . pasteur-02493687

HAL Id: pasteur-02493687

<https://hal-pasteur.archives-ouvertes.fr/pasteur-02493687>

Submitted on 28 Feb 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial - NoDerivatives | 4.0
International License



Short communication

Subcutaneous vaccination with a live attenuated *Yersinia pseudotuberculosis* plague vaccine

Anne Derbise^a, Chloé Guillas^{a,2}, Christiane Gerke^b, Elisabeth Carniel^{a,1}, Javier Pizarro-Cerdà^a, Christian E. Demeure^{a,*}

^a *Yersinia* Research Unit, Institut Pasteur, 28 rue du Dr Roux, 75724 Paris, France

^b Vaccine Programs, Institut Pasteur, 28 rue du Dr Roux, 75724 Paris, France

ARTICLE INFO

Article history:

Received 21 October 2019

Received in revised form 3 December 2019

Accepted 6 January 2020

Available online 18 January 2020

Keywords:

Bubonic plague

Pneumonic plague

Live vaccine

Yersinia pestis

Yersinia pseudotuberculosis

Subcutaneous

ABSTRACT

A single oral inoculation to mice of the live attenuated *Yersinia pseudotuberculosis* VTnF1 strain producing an F1 pseudocapsule protects against bubonic and pneumonic plague. However oral vaccination can fail in humans exposed to frequent intestinal infections. We evaluated in mice the efficacy of subcutaneous vaccine injection as an alternative way to induce protective immunity, while reducing the dose and avoiding strain release in nature. A single subcutaneous dose of up to 10^8 CFU induced dose-dependent antibody production. At the dose of 10^7 CFU, i.e. 10 times less than via the oral route, it caused a modest skin reaction and protected 100% against bubonic and 80% against pneumonic plague, caused by high doses of *Yersinia pestis*. Bacteria migrating to lymph nodes and spleen, but not feces, were rapidly eliminated. Thus, subcutaneous injection of VTnF1 would represent a good alternative when dissemination in nature and human intestinal responsiveness are limitations.

© 2020 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

1. Introduction

Despite efficient antibiotic treatments, plague lethality in endemic regions remains greater than 10% [1], mainly due to the fast development of pathogenesis. Plague is endemic in more than 25 countries worldwide (including Madagascar, RDC, USA, China, Peru) and in addition to permanent foci, plague is reappearing since few decades and is categorized by WHO (World Health Organization) as a re-emerging disease [1]. No vaccine is widely available. A live attenuated *Y. pestis* vaccine is used in Russia and China but requires yearly boosting [2]. Candidate recombinant vaccines under development in the USA, China are composed of F1 and LcrV (V) antigens. They have passed phase II clinical development but are not yet commercialized [3,4]. A micro-encapsulated F1-V vaccine was recently produced in Russia [5].

We recently proposed to use a live *Y. pseudotuberculosis* to vaccinate against plague. This species originated from the same ancestor as the plague agent and is genetically very closely related

but much less pathogenic. To this aim, a genetically defined *Y. pseudotuberculosis* strain was strongly attenuated by irreversible deletion of three loci encoding essential virulence factors (psaA, HPI, and yopK). It was modified to produce the *Y. pestis* F1 pseudocapsule by insertion of the *Y. pestis* *caf* operon, and named VTnF1. A single oral dose of VTnF1 generates both humoral and cell-mediated immune responses against multiple antigens of the bacteria and confers high-level protection against bubonic and pneumonic forms of plague [6].

VTnF1 was devised for the oral route because *Yersiniae* are enterobacteria which enter host gut secondary lymphoid tissues and strongly stimulate the host immune system, thus causing their own elimination. Although efficient for immunization, there are challenges for implementation. First, the oral route is not equally efficacious in different populations. Multiple intestinal infections alter the gut wall and immune system and reduce the efficacy of oral vaccination [7,8] and most of the human population at risk for plague (Madagascar, Congo, Tanzania, etc.) is also exposed to such intestinal infections. Second, the dissemination of a live organism vaccine in the environment via feces may be considered unacceptable by those who fear GMOs and consider possible the reversion to more virulence [9,10].

Vaccination by subcutaneous injection (sc; or hypodermal), intradermal or intramuscular injection could avoid these difficulties. The skin is an attractive site from an immunologic

* Corresponding author.

E-mail addresses: cdemeure@pasteur.fr, christian.demeure@pasteur.fr (C.E. Demeure).

¹ Present address: Pasteur Center of Cameroon, 1274 Yaoundé, Cameroon.

² Present address: Paris Centre de Recherche Cardiovasculaire (PARCC) - INSERM UMR 970, Hôpital Européen Georges Pompidou, 56, rue Leblanc, 75015 Paris, France.

perspective: it contains many resident dendritic cells which capture antigens and migrate to lymph nodes (LN) to present antigens and recruit T lymphocytes [11]. Vaccination via skin generally requires less vaccine as compared to the oral route, in which a large part is eliminated by the intestinal transit. Bacteria injected sc also should not be disseminated in nature. We here examined the possibility to subcutaneously vaccinate mice against plague using the VTnF1 live attenuated candidate vaccine.

2. Materials and methods

2.1. Ethics statement

The Institut Pasteur animal facility is accredited by the French Ministry of Agriculture (B 75 15-01, issued on May 22, 2008), in compliance with French and European regulations (EC Directive 86/609, French Law 2001-486; June 6, 2001). The research protocol was approved by the French Ministry of Research (N° 2013-0038).

2.2. Bacterial strains and culture conditions

The *Y. pseudotuberculosis* and *Y. pestis* isolates and their growth conditions were previously described [6,12]. All experiments involving *Y. pestis* strains were performed in a BSL3 laboratory or level 3 animal room.

2.3. Animal vaccination and in vivo analyses

Seven-week-old OF1 (outbred) female mice (Charles River) were housed and manipulated in a BSL3 animal facility as described previously [12]. Vaccination consisted of subcutaneous (sc) injection of a VTnF1 suspension (10^5 , 10^6 , 10^7 , or 10^8 CFU in 50 μ l saline) in the skin of the back. Mice were monitored daily for signs of prostration and aspect (ruffled hair) and were weighed. The skin reaction was scored as follows. 0: no papule; 1: not visible but perceptible by pinching the skin between fingers (≤ 1 mm), 2: visible but small (1–2 mm) between fingers; 3: ≥ 2 mm between fingers. To examine *in vivo* VTnF1 dissemination, groups of mice were euthanized after predefined times and skin at the injection site (2 cm²), draining LN, and spleen were collected aseptically. They were homogenized in sterile PBS using 3 mm glass beads (soft tissues) or steel beads (skin) and an electric mill (TissueLysor®, Qiagen). Samples were plated on LB-agar containing Kanamycin and Spectinomycin. The presence of VTnF1 in feces was tested by plating 2–3 pellets per mouse.

2.4. Plague challenge experiments

Mice were challenged four weeks after vaccination with *Y. pestis* CO92 resuspended in saline after growth at 28 °C on LBH plates. Bubonic plague was induced by sc injection in the ventral skin. For pneumonic plague, it had been reported that too low volumes of bacteria instilled intranasally mostly stay in the upper respira-

tory tract [13,14]. Using bioluminescent *Y. pestis* [6], we observed that lung colonization was obtained when 20 μ l of bacteria (10 μ l per nostril) were instilled (Supplementary Fig. 1). Therefore, mice were infected as previously described [6], except the volume of 20 μ l was used. Survival was followed for 21 days (Supplementary Fig. 1).

2.5. Evaluation of the immune response

Mouse blood was collected three weeks after vaccination and serum IgG directed against F1 or a *Y. pestis* Δ caf sonicate were measured as previously described [6,12].

3. Statistical analyses

The Fisher exact test (for mice survival), the unpaired Mann-Whitney test (for bacteria numbers, animal weight, and antibody titers) were performed with Prism® (GraphPad).

4. Results and discussion

4.1. The VTnF1 candidate vaccine strain injected subcutaneously is avirulent and induces a protective immune response

Increasing doses of VTnF1 (10^5 to 10^8 CFU tested altogether in 24, 24, 46, and 38 mice respectively) were injected subcutaneously to OF1 mice in the back. No lethality and no clinical signs of illness were observed over a 4 weeks post vaccination follow-up, showing that VTnF1, strongly attenuated via the oral route [6], is also highly attenuated via a parenteral route (sc). This also indicates that the attenuation affected the bacteria's ability to survive in the host body, and not only its capacity to infect the gut.

To evaluate protection against bubonic plague, mice received a single injection of VTnF1 (10^5 to 10^8 CFU) and were challenged 4 weeks after by ventral sc injection of *Y. pestis* (severe bubonic plague challenge: $10,000 \times LD_{50}$, = 10^5 CFU). High-level protection (96–100%) was obtained with the 10^7 CFU dose and higher (Table 1). Therefore, protection via the sc route required a dose at least 10-times lower than via the oral route [6].

The protection induced by sc and ig vaccination against pneumonic plague were compared using recently modified conditions to induce airways infection modified recently (see materials and methods). Both routes conferred around 80% protection (Table 1) against pneumonic plague caused by a high dose of *Y. pestis* CO92 (10^7 CFU = $3,300 \times LD_{50}$) and increasing the sc dose to 10^8 CFU did not increase protection.

Y. pestis-specific IgG were measured in the serum of vaccinated mice. Vaccination induced a strongly dose-dependent production of IgG directed to either F1 (Fig. 1A) or all other *Yersinia* antigens (F1- *Y. pestis*; Fig. 1B). Antibody titers were compared to those of oral VTnF1. Sc injection induced comparable amounts of IgG against F1, and more IgG against other *Yersinia* antigens

Table 1

Protection of mice by subcutaneous or intragastric vaccination with VTnF1 against bubonic and pneumonic plague. Mice having received a single subcutaneous dose of VTnF1 were challenged 4 weeks later by infection with *Y. pestis* CO92 s.c. (bubonic plague; 10^5 CFU) or i.n. (pneumonic plague; 10^7 CFU). Survival was recorded daily for 21 days. Survival from bubonic plague observed with VTnF1 given ig is reported here for comparison, and was first reported in Derbise A. et al. PLoS NTD. 2015. Protection significance compared to naïve mice was tested using Fisher's two-tailed exact test: ***: $p < 0.001$; ****: $p < 0.0001$.

	Subcutaneous VTnF1					Intragastric VTnF1							
	Bubonic plague					Pneumonic plague			Bubonic pl.			Pneumonic pl.	
Vaccine dose (CFU)	0	10^5	10^6	10^7	10^8	0	10^7	10^8	0	10^7	10^8	0	10^8
Survivors/total	0/16	13/24	23/24	16/16	8/8	0/23	24/30	25/30	1/16	6/8	13/14	0/8	13/15
% survival	0	54	96	100	100	0	80	83	6	75	93	0	87
Significance		***	****	****	****		****	****		*	***		****




Fig. 1. Immune response of vaccinated mice. Groups of mice were injected sc (14/ group gathered from 2 experiments) or inoculated ig (30–37 mice gathered from 3 experiments) with graded doses of live VTnF1 and blood was taken 3 weeks. Serum IgG against purified F1 (A) or other *Y. pestis* antigens (CO92 Δ caf lysate: all antigens except F1; B) were measured in sera by Elisa. Mann-Whitney test; *: $p \leq 0.05$; **: $p \leq 0.001$; ****: $p \leq 0.0001$; ns: not significant.

(F1- *Y. pestis*; Fig. 1A & B) than ig inoculation. VTnF1 at dose 10^7 given ig yields heterogenous IgG titers and lower protection (Fig. 1 and [15]). Altogether, the vaccine given sc is as efficient in terms of antibody production (Fig. 1) and protection (Table 1), as when it is given ig at a higher dose. One explanation to the higher IgG response after sc vaccination may be that bacteria trapped in skin are available to trigger the immune system, whereas part of bacteria via ig is killed by acidity in the stomach, or fail to bind PP and are washed away in feces. Similarly, Zhao and co-workers recently reported that the sc route provided higher protection than the oral route for mice vaccination with a live *Salmonella* vector producing *Salmonella* or *Bordetella* antigens [16]. Indeed, the skin is permanently patrolled by active dendritic cells which sample the foreign material to trigger the immune response [17].

A key reason to evaluate the cutaneous route was that the gut immune system of subjects exposed to repeated oral infections has a reduced ability to respond to immunization, thus reducing the efficacy of oral vaccines [7,8]. Such an impairment has so far not been reported regarding the skin immune system, suggesting that skin vaccination remains a valid prophylactic approach in these populations.

4.2. VTnF1 causes little side effects and disseminates transiently in vivo

Although the subcutaneous route is widely used for live attenuated viruses (Varicella, measles, mumps [18]), injection of live




Fig. 2. Follow-up of vaccinated mice. Mice were vaccinated sc with VTnF1 (triangles), or were left unvaccinated (naïves: circles) and were followed for 3 weeks for their weight (A) and the size of the reaction at the skin site of vaccination (B; 0: undetectable; 1: not visible but perceptible (≤ 1 mm) by pinching, 2: visible but small (1–2 mm); 3: ≥ 2 mm). Shown are means \pm s.e.m. of 15 (A) or 8 (B) mice per group. The statistical significance was evaluated using the unpaired Student *t* test). *: $p \leq 0.05$; **: $p \leq 0.01$; ***: $p \leq 0.001$.

attenuated bacteria is not usual, possibly due to side effects with candidate vaccines tested previously [19]. Because VTnF1 is highly attenuated and is efficient at the dose of 10^7 CFU, we characterized side-effects at that dose. After injection, half of mice had ruffled fur at day 2, and most had recovered at day 5. Skin papules at the site of injection were always palpable (Fig. 2A), but were generally not visible by eye, except in 10% of mice who exhibited a local hair loss, which always regrew to normal afterwards. A reduction of weight acquisition was observed at day 3, but growth rapidly normalized later on (Fig. 2B). Because humans are more sensitive to LPS than mice [20], a reaction of human tissues to LPS contained in the vaccine may happen, and this will carefully be examined in future developments. LPS detoxification by deletion of *msbB* or *htrB* genes controlling lipid-A acylation could be considered, as previously reported in *Shigella* [21].

VTnF1 dissemination from the skin to the draining lymph nodes and the spleen was examined (Fig. 3). Bacteria persisted at the skin entry site up to day 5 and then declined, so that most mice were negative after 3 weeks. At day 1–2, VTnF1 was observed in spleen and draining lymph nodes, suggesting a simultaneous migration to spleen via blood and to lymph nodes via lymphatics. VTnF1 loads peaked in all sites at day 5, prior to a progressive disappearance in LN and spleen after day 9. This transient persistence was therefore comparable, in its evolution and levels, to that observed after oral vaccination with the higher dose, in good agreement with the comparable immunization.




Fig. 3. In vivo dissemination of sc-injected VTnF1. Groups of mice were injected sc with 10^7 CFU VTnF1 and were sacrificed at predetermined times. Organs and feces were collected and homogenized for bacteria load determination. Individual results from 7 mice per group are shown for skin (2 cm² around the site of injection), DLN from both sides, the whole spleen and 2–3 fecal pellets. The median is shown as a red horizontal bar. The dotted line indicates the limit of detection.

The subcutaneous tissue in which the bacteria were injected, also named hypodermis, is a well vascularized layer of adipose tissue and the most used skin layer for delivery of live attenuated virus vaccines. There, the vaccine meets dendritic cells, the antigen-presenting cells (APCs) which can handle it and present its antigens to T cells in LN [17]. Although the subcutaneous tissue is less drained by lymphatics than the actively surveyed dermis layer, injected particles succeed to reach LN via lymph to trigger adaptive immunity [22]. Because VTnF1 rapidly reached both LN and spleen (day 1), it must have gained access to both blood and lymphatic vessels, and this may result from a mechanical damage caused by injection. Alternatively, antigens could also be carried to LN by specialized antigen presenting cells. Because the hypodermis is naturally devoid of resident immune cells, these would be recruited from dermis or blood.

The risk of bacteria passage in the environment was evaluated by searching for VTnF1 in feces. Feces were analyzed regularly up to one month post inoculation, and no VTnF1 was detected (Fig. 3). Although it seems trivial that skin is not directly connected to the intestine, the transit of bacteria via blood could have redirected it to unexpected organs, as was observed for *Listeria monocytogenes* moving from blood to the intestine [23]. The absence of vaccine in feces demonstrates that it did not reach the gut lumen, and that fecal dissemination of this GMO in nature is very unlikely. For future use, we are re-constructing the VTnF1 strain without any antibiotics-resistance cassettes (unpublished data), and this will increase safety for both vaccinated subjects and in case of accidental release.

In conclusion, we have shown that subcutaneous vaccination with the recombinant attenuated *Y. pseudotuberculosis* vaccine strain VTnF1 efficiently immunized and protected mice against bubonic and pneumonic plague, with an optimal dose lower than required for oral vaccination. Because it also avoids dissemination of the vaccine in nature, the hypodermal route may be an interesting alternative to oral vaccination when its efficacy is impaired, such as often observed in developing countries.

CRediT authorship contribution statement

Anne Derbise: Conceptualization, Methodology, Investigation, Writing - review & editing. **Chloé Guillas:** Investigation. **Christiane Gerke:** Validation, Writing - review & editing. **Elisabeth Carniel:** Conceptualization, Supervision, Project administration. **Javier Pizarro-Cerdà:** Conceptualization, Supervision, Project administration. **Christian E. Demeure:** Conceptualization, Methodology, Investigation, Writing - review & editing, Project administration.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

The project was supported by an ANR Emergence grant (ANR-12-EMMA-0011-01) and an Institut Pasteur Accelerating Preclinical Candidates - GPF- Vaccinology 2015 grant (GPFVacc2-08). The authors would like to thank the Institut Pasteur Central animal facility team for their support with mouse hosting and care.

Appendix A. Supplementary material

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.vaccine.2020.01.014>.

References

- [1] Bertherat E. Plague around the world in 2019. In: WHO, editor. Weekly Epidemiologic Reports: WHO; 2019. p. 289–92.
- [2] Feodorova VA, Motin VL. Plague vaccines. In: Motin VAFaVL, editor. Vaccines against bacterial bioterror pathogens. Kerala, India: Research SignPost; 2011. p. 175–233.
- [3] DynPort Vaccine Company. Recombinant Plague Vaccine rF1V in Healthy Volunteers. ClinicalTrials.gov: NIH. U.S. National Library of Medicine; 2011.
- [4] Jiangsu Province CDC. Immunogenicity and Safety of Subunit Plague Vaccine. ClinicalTrials.gov: NIH. U.S. National Library of Medicine; 2015.
- [5] Mikshis NI, Kuttyrev VV. Current state of the problem of vaccine development for specific prophylaxis of plague. Problems Particul Dangerous Infect (Russian) 2019;1:50–63.
- [6] Derbise A, Hanada Y, Khalife M, Carniel E, Demeure CE. Complete protection against pneumonic and bubonic plague after a single oral vaccination. PLoS Negl Trop Dis 2015;9:e0004162.
- [7] Holmgren J, Svennerholm AM. Vaccines against mucosal infections. Curr Opin Immunol 2012;24:343–53.
- [8] Levine MM. Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccine. BMC Biol 2010;8:129.
- [9] Frey J. Biological safety concepts of genetically modified live bacterial vaccines. Vaccine 2007;25:5598–605.
- [10] Minor P. Vaccine-derived poliovirus (VDPV): Impact on poliomyelitis eradication. Vaccine 2009;27:2649–52.
- [11] Kupper TS, Fuhlbrigge RC. Immune surveillance in the skin: mechanisms and clinical consequences. Nat Rev Immunol 2004;4:211–22.
- [12] Derbise A, Cerdà Marín A, Ave P, Blisnick T, Huerre M, Carniel E, et al. An encapsulated *Yersinia pseudotuberculosis* is a highly efficient vaccine against pneumonic plague. PLoS NTD 2012;6:e1528.
- [13] Olson RM, Anderson DM. Shift from primary pneumonic to secondary septicemic plague by decreasing the volume of intranasal challenge with *Yersinia pestis* in the murine model. PLoS ONE 2019;14:e0217440.
- [14] Southam DS, Dolovich M, O'Byrne PM, Inman MD. Distribution of intranasal instillations in mice: effects of volume, time, body position, and anesthesia. Am J Physiol Lung Cell Mol Physiol 2002;282:L833–9.

- [15] Demeure CE, Derbise A, Guillas C, Gerke C, Cauchemez S, Carniel E, et al. Humoral and cellular immune correlates of protection against bubonic plague by a live *Yersinia pseudotuberculosis* vaccine. *Vaccine* 2019;37:123–9.
- [16] Zhao Z, Xue Y, Wu B, Tang X, Hu R, Xu Y, et al. Subcutaneous vaccination with attenuated *Salmonella enterica* serovar Choleraesuis C500 expressing recombinant filamentous hemagglutinin and pertactin antigens protects mice against fatal infections with both *S. enterica* serovar Choleraesuis and *Bordetella bronchiseptica*. *Infect Immun* 2008;76:2157–63.
- [17] Kashem SW, Haniffa M, Kaplan DH. Antigen-Presenting Cells in the Skin. *Annu Rev Immunol* 2017;35:469–99.
- [18] Iannelli V. Which Vaccines can be Given SQ? In: Vaxopedia, editor; 2019. p. vaxopedia.org/2018/04/10/which-vaccines-can-be-given-sq/.
- [19] Lindberg AA. The history of live bacterial vaccines. *Dev Biol Stand* 1995;84:211–9.
- [20] Warren HS, Fitting C, Hoff E, Adib-Conquy M, Beasley-Topliffe L, Tesini B, et al. Resilience to bacterial infection: difference between species could be due to proteins in serum. *J Infect Dis* 2010;201:223–32.
- [21] Rossi O, Pesce I, Giannelli C, Aprea S, Caboni M, Citiulo F, et al. Modulation of endotoxicity of *Shigella* generalized modules for membrane antigens (GMMA) by genetic lipid A modifications: relative activation of TLR4 and TLR2 pathways in different mutants. *J Biol Chem* 2014;289:24922–35.
- [22] Kabashima K, Honda T, Ginhoux F, Egawa G. The immunological anatomy of the skin. *Nat Rev Immunol* 2019;19:19–30.
- [23] Quereda JJ, Nahori MA, Meza-Torres J, Sachse M, Titos-Jimenez P, Gomez-Laguna J, et al. Listeriolysin S Is a Streptolysin S-Like Virulence Factor That Targets Exclusively Prokaryotic Cells In Vivo. *MBio*. 2017;8.